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Abstract 27 
Anti-inflammatory modalities are commonly used for the treatment of various 28 
musculoskeletal injuries. While inflammation was originally believed to interfere with skeletal 29 
muscle regeneration, several recent studies have highlighted the beneficial effects of 30 
inflammatory cells on muscle healing. This discrepancy is attributable to our evolving 31 
understanding of the complex inflammatory process. To better appreciate the paradoxical 32 
roles of inflammation, clinicians must have a better comprehension of the fundamental 33 
mechanisms regulating the inflammatory response. In this perspective paper, we analyzed 34 
cellular, animal and human studies to summarize recent knowledge regarding inflammation’s 35 
impact on muscle regeneration in acute or chronic conditions. We also discussed the effect 36 
of anti-inflammatory drugs in the treatment of various muscle injuries. Overall, this work aims 37 
to summarize the current state of the literature on the inflammatory process associated with 38 
muscle healing in order to give clinicians the necessary tools to have a more efficient and 39 
evidence-based practice for the treatment of muscle injuries and disorders. 40 
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Introduction 55 
  56 
The majority of physical therapists are confronted in their everyday work with different types 57 
of musculoskeletal injuries. One common feature for most of these injuries is the presence of 58 
an inflammatory response, which can be acute or chronic, mild or severe, and septic or 59 
sterile. Physiotherapists possess different physical, thermal, electrotherapeutic, and even 60 
molecular tools that dampen, to varying degrees of efficiency, the inflammatory response. 61 
Notably, in 2013, physiotherapists from the UK were the first to obtain the right to prescribe 62 
non-steroidal anti-inflammatory drugs (NSAIDs) (1). Physiotherapists from other countries, 63 
such as New-Zealand, Australia, Canada, United States and others, do not yet have the 64 
legislative right to prescribe NSAIDs or any other analgesics; nevertheless, a high proportion 65 
of physiotherapists will directly recommend NSAIDs or will emphasize to their patients the 66 
importance of seeking advice from their pharmacist or physician (2,3). However, multiple 67 
studies suggested that their knowledge on NSAIDs is incomplete or inadequate (3,4). The 68 
results from a survey targeting physiotherapists from different countries showed that most 69 
physiotherapists did not recently upgrade their knowledge on NSAIDs use (5). Another study 70 
on the perception of physiotherapists on NSAIDs showed that (1) the majority of 71 
physiotherapists believed that NSAIDs are more efficient than analgesic (acetaminophen) to 72 
relieve pain in musculoskeletal injuries, and (2) less than half of the physiotherapists 73 
believed that NSAIDs should be withheld during the first few days after an injury to avoid 74 
interfering with the beneficial effect of inflammation (3). These results reveal contradictory 75 
views on the efficacy of anti-inflammatory drugs among physiotherapists, which result from  76 
a lack of knowledge regarding the effect of inflammation on tissue healing. While the 77 
academic curricula recently changed in some countries to include additional information on 78 
the use of different anti-inflammatory drugs, we believe that an update of this fast-evolving 79 
field will bring novel and clinically important information to physiotherapists. 80 
         In a recent paper published in Physical Therapy Journal, Norland R et al indicate that 81 
a gap exists between basic science research and clinical practices (6). The authors 82 
 4 
suggested that health professionals would benefit from integrating the notion of regenerative 83 
rehabilitation, which combines rehabilitation with regenerative medicine (such as biomaterial 84 
or cell therapies), to their practice in order to provide an optimal environment for tissue 85 
healing (6,7). For clinicians to do so, however, academics must ensure that the recent 86 
advances in fundamental biological sciences are accessible and can be implemented in a 87 
clinical setting. In agreement, we believe that to understand the efficacy of anti-inflammatory 88 
modalities, clinicians must first comprehend the fundamental nature and function of the 89 
inflammatory process. In this review, we describe the interactions between inflammatory 90 
cells and satellite cells, the latter of which are responsible for muscle regeneration (see table 91 
1 for the description of the different cell types). We compare the effect of the inflammatory 92 
process in acute and chronic injury and analyze the efficacy of NSAIDs on muscle healing. 93 
  94 
Muscle regeneration 95 
Skeletal muscles constitute approximately 30-40% of total body mass and have many vital 96 
roles such as generation of movement, protection, breathing, thermoregulation and 97 
metabolism. Movement is generated by the contraction of long cylindrical cells named 98 
myofibers, which are the most important part of skeletal muscle composition (8). The 99 
integrity and the function of these cells can be affected by different traumas and conditions 100 
such as strains, contusions, lacerations, immobilisation, eccentric-induced muscle damage, 101 
ischemia and others. Because the nuclei of the myofibers are terminally post-mitotic (i.e. 102 
they cannot divide anymore), muscle regeneration is ensured by a population of adult 103 
muscle stem cells, named satellite cells (9). In absence of satellite cells, skeletal muscle 104 
regeneration post-injury is prevented (10,11). One exception is skeletal muscle hypertrophy 105 
(a process that does not affect the cellular integrity of myofibers), where an increase in 106 
myofiber size is possible in absence of satellite cells, although it plateaus faster and it is 107 
associated with signs of impaired healing such as fibrosis deposition (12,13). Overall, 108 
satellite cells are essential to muscle regeneration post-injury, and they also contribute to 109 
muscle hypertrophy.   110 
 5 
Following an injury, satellite cells activate and become myoblasts that proliferate extensively 111 
for the first few days (Figure 1). Three to seven days after the injury, myoblasts stop 112 
proliferating to differentiate and either fuse to the damaged myofibers or fuse together to 113 
form myotubes (immature myofibers). During the next few weeks, these newly formed 114 
myofibers grow to form new mature myofibers. In murine models, this very efficient process 115 
explains the remarkable regenerative capacity of murine skeletal muscles, which can largely 116 
regain their integrity and function only a few weeks following a severe injury (14). While 117 
human skeletal muscles also have an important regenerative capacity, it might not be as 118 
efficient. Accordingly, it was shown that muscle morphology can still be altered long after an 119 
injury (15). Notably, both in animals and humans, muscle injury also activates an 120 
inflammatory response characterized by the coordinated recruitment of inflammatory cells to 121 
the site of injury (16). The onset, development, and resolution of the inflammatory process 122 
have a critical role on the guidance of satellite cell function and thus, on muscle regeneration 123 
(17). 124 
  125 
The acute inflammatory process 126 
While physiotherapy treatments aim at decreasing clinical signs of inflammation such as 127 
swelling, pain and loss of function, the cellular and molecular mechanisms governing the 128 
inflammatory process remain elusive for many. This could be partially explained by the fact 129 
that the definition of inflammation continues to evolve alongside the advances in modern 130 
molecular biology. Indeed, while inflammation was first defined solely based on clinical signs 131 
and symptoms, it is now known that it involves a broad spectrum of inflammatory conditions 132 
that are initiated by different stimuli and that activates a multitude of complex biological 133 
processes (18). Sterile inflammation, occurring in acute pathogen-free conditions such as 134 
sport injuries, has been extensively studied in the last decade, and a large body of evidence 135 
has emerged regarding the influence of inflammatory cells on the healing process. While 136 
human studies are more easily transferable to physical therapy practice, animal and cellular 137 
studies have allowed us to increase our understanding of inflammation by developing 138 
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several information-rich experimental models (16). In the next section, we will use these 139 
human, animal and cellular models of muscle injury to discuss the different phases of the 140 
inflammatory process, i.e. the onset, the development, and the dampening of inflammation.  141 
Onset of the inflammatory process: Injury-induced disruption of blood vessel integrity 142 
has long been considered as the starting point of the inflammatory process by activating the 143 
blood coagulation cascade, which, among other roles, leads to the formation of 144 
anaphylatoxins. These small molecules activate sentinel cells residing in muscle tissue 145 
(resident cells), such as mast cells, which triggers sterile inflammatory responses (19). In 146 
addition to anaphylatoxins, it is now known that tissue damage also liberates intracellular 147 
proteins and molecules normally sequestered in the extracellular matrix, which activate 148 
resident cells once they are released at the site of the injury (20). In other words, the 149 
mechanical stress induced by a traumatic muscle injury releases a wide variety of factors 150 
that activate different resident cell types to initiate the inflammatory process(21). In addition 151 
to their role in the orchestration of the inflammatory process, the factors released by mast 152 
cells also directly stimulate the proliferation of satellite cells (22,23). These findings indicate 153 
that inflammatory cells coordinate the muscle healing process right from the start. 154 
Development of the inflammatory process: One of the major roles of the early 155 
mediators of inflammation released by resident cells is to increase vasodilatation, vascular 156 
permeability and the expression of adhesion molecules to allow the infiltration of 157 
inflammatory cells into peripheral tissues from the blood circulation (24). The first cell type to 158 
migrate into the injured tissue from the blood are neutrophils, followed by blood monocytes 159 
which are converted into macrophages when reaching muscle tissues (25). Neutrophils are 160 
able to phagocytose cell debris in order to clean the injured zone; however, they also release 161 
proteolytic enzymes and reactive oxygen species that can induce induce secondary damage 162 
to the intact tissue near the injured zone (16,26). This detrimental side effect is dependent 163 
on the type and the intensity of the muscle injury; in other words, a severe muscle injury 164 
leads to more important neutrophil-induced collateral damage compared to a mild injury (27). 165 
During this inflammatory phase, which typically lasts 72 hours, both neutrophils and 166 
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macrophages, along with other resident cell types (e.g. endothelial cells, fibroblasts, 167 
myofibers and satellite cells), release cytokines (i.e. secreted proteins important for cell 168 
signalling) that stimulate inflammatory cell recruitment (16).  169 
Resolution of the inflammatory process: Contrary to the original belief that the 170 
dampening of the inflammatory response is a passive process caused by the arrest of pro-171 
inflammatory factor secretion, recent discoveries showed that resolution of inflammation is 172 
an active step that involves complex cellular and molecular interactions (28). At the cellular 173 
level, it was shown that macrophages switch from a pro-inflammatory phenotype (M1 174 
macrophages) to an anti-inflammatory phenotype (M2 macrophages) approximately 2 days 175 
after a muscle injury (29). Additionally, these subsets of macrophages have very different 176 
functions. M1 macrophages phagocytose muscle cell debris and release pro-inflammatory 177 
factors that stimulate myoblast proliferation. On the other hand, M2 macrophages release 178 
anti-inflammatory molecules and growth factors that stop myoblast proliferation and 179 
stimulate their differentiation, fusion, and myofiber growth. Therefore, the switch in 180 
macrophage phenotype is essential to a timely coordination of the activity of myogenic cells. 181 
A similar switch was also observed at the molecular level during muscle regeneration, where 182 
the biosynthesis of proinflammatory lipid mediators is progressively replaced by anti-183 
inflammatory and pro-resolving lipid mediators. This programmed class-switching of lipid 184 
mediators supports the idea that the resolution of inflammation is predetermined from the 185 
beginning of the inflammatory response (28,30,31). Particularly, the enzyme cyclooxygenase 186 
(COX)-2 is directly implicated in this lipid mediator class-switching. Both proinflammatory 187 
and anti-inflammatory molecules are generated by COX-2 at different stages of the 188 
inflammatory process (32,33), which is particularly important because COX-2 is the enzyme 189 
targeted by NSAIDs. Since physiotherapists are frequently treating patients consuming 190 
NSAIDs, they should be aware that COX-2 inhibition does not only blunt the pro-191 
inflammatory response but also inhibit the resolution of inflammation, which has a direct 192 
effect on muscle healing. 193 
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Overall, muscle regeneration is intimately related to the different phases of inflammation in 194 
the context of acute injury (Figure 2: upper panel). Coordinated inflammatory cell recruitment 195 
orchestrates satellite cell activity and ensures optimal muscle recovery. Because of the 196 
importance of physiotherapy in the optimization of the repair phase, the relationship between 197 
inflammation and muscle regeneration will be further discussed in the following section. 198 
 199 
The impact of NSAIDs on acute muscle healing 200 
The enthusiasm for the use of anti-inflammatory drugs in order to control the inflammatory 201 
process has pushed many research groups to study the impact of partial or complete 202 
inhibition of inflammation on muscle repair. Inhibition of COX-2 with specific inhibitors or 203 
using COX-2-deficient animal models demonstrated that blocking this pathway diminishes 204 
proliferation, differentiation and fusion of satellite cells, and results in impaired skeletal 205 
muscle growth, delayed skeletal muscle repair and increased fibrosis (34,35). In human, 206 
administration of NSAIDs failed to improve the efficacy of physiotherapy treatment following 207 
acute hamstring injury (36). Moreover, using a model of maximal eccentric contractions-208 
induced muscle injury in humans, Mikkelsen et al. have demonstrated that local injections of 209 
indomethacin, a nonspecific COX inhibitor, by microdialysis catheters into the vastus lateralis 210 
muscle for 7.5 hours during the exercise day suppressed the exercise-induced increase of 211 
satellite cells at day 8 post-exercise (37). Mackey et al. reached the same conclusion by 212 
studying muscle biopsies of healthy male endurance athletes that received 100 mg of 213 
indomethacin every day from 4 days before a 36-km run-induced muscle injury until day 8 214 
post-run (38). In another study, the same first author showed that ibuprofen-treated young 215 
men have higher satellite cell content 7 days after an electrical stimulation-induced muscle 216 
injury compared to the placebo group. These results suggest that there are differences in 217 
satellite response to NSAIDs depending on the type of injury. 218 
Muscle protein synthesis is also affected by NSAID consumption. In a murine model of 219 
chronically overloaded plantaris muscle (induced by the surgical removal of the 220 
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gastrocnemius and soleus), the administration of nonspecific COX inhibitor ibuprofen in the 221 
drinking water of rats inhibited plantaris hypertrophy by 50% following 14 days of overloading 222 
(39). Similar results were also observed in mice (40). In contrast, using an experimental 223 
procedure on healthy elderly patients in which one lower limb was immobilized in a cast 224 
during 2 weeks followed by 6 weeks of retraining, Dideriksen et al showed that NSAID 225 
consumption (ibuprofen 1,200 mg/day) did not affect muscle mass and strength (41). 226 
However, their NSAID treatment did not significantly affect the circulating levels of 227 
inflammatory markers. Therefore, because of differences in the type of injury, its severity, 228 
and the efficacy of the anti-inflammatory modality used across studies, some discrepancies 229 
exist on the effect of NSAIDs on muscle regeneration. Nonetheless, there is accumulating 230 
evidence indicating that the dampening of the inflammatory process during acute injuries 231 
leads to impaired muscle growth and regeneration in animals and humans.  232 
Different animal models were used to analyze the specific impact of each individual 233 
inflammatory cell type during muscle healing. For instance, by specifically depleting 234 
neutrophils, it has been shown that even if these cells are known to induce secondary 235 
damage during the inflammatory process, they also contribute to muscle growth and repair 236 
by cleaning cell debris and activating satellite cells (42). Moreover, injured muscles of mice 237 
depleted of neutrophils present larger areas of necrotic tissue than control mice at 7 days 238 
post-injury (43). Other inflammatory cells, the monocytes/macrophages (monocytes circulate 239 
in blood and become macrophages once they migrated in the tissue) have been much more 240 
extensively studied in the literature for their role on muscle repair. Many studies have 241 
demonstrated that impaired macrophage accumulation leads to defective skeletal muscle 242 
healing. For example, by depleting blood monocytes, Summan et al. have established that 243 
the decrease in macrophage accumulation in the injured muscle was accompanied with 244 
persistent necrotic myofibers and increased fat accumulation into muscle at days 9 and 14 245 
post-injury, respectively (44). Accordingly, Arnold et al. (2007) showed that the depletion of 246 
blood monocyte at the time of injury entirely prevented muscle regeneration whereas the 247 
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depletion of intramuscular macrophages from day 5 post-injury caused a reduction in 248 
myofiber diameter (29). Similar conclusions have been reported by many other groups using 249 
various models (45,46). Taken together, these results clearly indicate that (1) the various 250 
phases of the inflammatory process play a critical role in orchestrating muscle regeneration 251 
following an acute injury and (2) pharmacological inhibition of the inflammatory process 252 
impairs acute muscle healing. 253 
To optimize physical therapy treatments, it is essential to associate the patient’s clinical 254 
symptoms to the ongoing muscular healing phase. Therefore, physiotherapists must 255 
understand inflammation on a fundamental level to determine whether anti-inflammatory 256 
modalities will delay or optimize muscle repair. Notably, anti-inflammatory properties of a 257 
treatment are commonly confounded with its analgesic effect. For instance, cryotherapy has 258 
a null to mild effect on pro-inflammatory markers following exercise-induced muscle damage 259 
(47). Moreover, the administration of ibuprofen (1,200 mg per day) did not significantly 260 
reduced the infiltration of neutrophils or macrophages following exercise-induced muscle 261 
damage (48,49). Thus, it is important to keep in mind that many therapeutic modalities have 262 
a limited effect on inflammation and act mostly on pain reduction. Since pain is a frequently 263 
reported symptom, the analgesic versus anti-inflammatory effect of a given modality must be 264 
fully understood by physiotherapists to determine the best therapeutic approach in order to 265 
promote patient recovery. 266 
 267 
The chronic inflammatory process 268 
Skeletal muscle has an impressive ability to respond to its local or systemic environment. 269 
This plasticity is essential for skeletal muscle adaptation to exercise or growth stimuli, but it 270 
can be deleterious in the context of chronic inflammation. The persistence of pro-271 
inflammatory signals affects the regenerative capacity of satellite cells and consequently 272 
impairs skeletal muscle healing leading to inappropriate repair mechanisms, such as muscle 273 
fibrosis and fat accumulation (50,51). These unresolved inflammatory events can originate 274 
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from local perturbations (e.g. repetitive muscle traumas, muscle dystrophies) or systemic 275 
disorders (e.g. cancer, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis) 276 
(52,53). In contrast to the literature on acute inflammation, the overall quality of evidence on 277 
the influence of chronic inflammation on muscle repair is relatively weak. Here, we discuss 278 
well-supported studies in order to understand the physiological impact of local or systemic 279 
factors-induced chronic inflammation on skeletal muscle healing. 280 
Systemic factors: Different groups have conducted elegant studies to document the 281 
effect of the systemic environment on the muscle repair process (54,55). Particularly, it was 282 
shown that aging is related to a higher concentration of pro-inflammatory systemic factors 283 
(also called “inflammaging”), which impairs the resolution of the inflammatory process and 284 
contributes to different diseases (56). This chronic up-regulation of pro-inflammatory factor 285 
levels impairs macrophage polarization shift from M1 toward M2 (57,58). Using different 286 
animal experiments, it was demonstrated that the rise in the expression of systemic pro-287 
inflammatory factors during aging directly impairs skeletal muscle healing. For example, an 288 
allograft experiments between young and old rats showed that a muscle collected from an 289 
old rat and transplanted into a young animal has improved muscle regeneration compared to 290 
a muscle collected from a young rat and transplanted into an old rat (55). Likewise, 291 
connecting the blood circulatory system of an old mouse to that of a young mouse improves 292 
satellite cell function in the old mouse (54). Altogether, these results indicate that systemic 293 
factors directly influence the cells involved in skeletal muscle healing and growth. 294 
In addition to slowing down the repair process, there is evidence indicating that this chronic 295 
low-grade inflammatory state is associated with a reduction in the synthesis and an up-296 
regulation in the degradation of contractile proteins in muscle fibers (59). Systemic pro-297 
inflammatory factors produced in conditions such as COPD (60), chronic kidney disease (61) 298 
and aging (62,63) were demonstrated to be associated with muscle wasting. Some of the 299 
systemic factors affecting skeletal muscle healing and growth have been identified. High 300 
levels of tumor necrosis factor-alpha (TNF-alpha), were detected in the serum of patients 301 
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with COPD and were correlated with impaired myoblast differentiation and muscle wasting 302 
(also known as cachexia) (64). Similarly, high levels of the pro-inflammatory cytokine 303 
interleukin-6 (IL-6) were observed in the serum of patients suffering from different 304 
pathologies such as prostate cancer (65) and also in the serum of healthy patients during 305 
aging (66,67). Notably, IL-6 was shown to impair satellite cell function (68) and promote 306 
muscle wasting (69). Overall, these studies indicate that many chronic disorders generate 307 
systemic pro-inflammatory factors that impair muscle healing.  308 
Local factors: As discussed previously, muscle healing is a tightly coordinated 309 
process, which is regulated by various molecular and cellular components that evolve during 310 
the different healing phases (Fig 2, upper panel) (70). However, a second injury to an 311 
already regenerating muscle can desynchronize this healing process (29,71). To study the 312 
effect of asynchronous muscle regeneration, Dadgar et al. used a mouse model in which 313 
muscles were injured with an intramuscular injection of notexin (toxin from snake venom) 314 
and then followed by a second injection 4 or 10 days later (repetitive local injuries) (71). 315 
Successive muscle injuries separated by 4 days led to a prolonged and persistent 316 
inflammatory response, while muscle injuries separated by 10 days caused an exaggerated 317 
production of the pro-fibrotic factor TGF-beta (transforming growth factor-beta), which led to 318 
muscle fibrosis (71). Similarly, another study showed that repetitive muscle injuries 319 
(intramuscular toxin injection 3 times every 5 days) lead to the exhaustion of the number of 320 
satellite cells (72). Altogether, these results showed that local interferences of the myogenic 321 
process strongly impair muscle healing. 322 
A similar pattern of chronic muscle injuries is observed in Duchenne muscular dystrophy 323 
(DMD), a severe genetic disease characterized by a mutation in the gene that encodes for 324 
the structural protein dystrophin. In absence of dystrophin, the muscle fibers are fragile and 325 
prone to injury, which leads to repetitive cycles of degeneration and regeneration. Muscle 326 
biopsies from patients suffering of DMD have shown that inflammatory cells and pro-327 
inflammatory molecules are highly expressed at various stages of the disease (73). 328 
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Consequently, macrophages are chronically present in the muscle, where they fail to switch 329 
to the anti-inflammatory phenotype (M2 macrophages) and rather adopt an hybrid phenotype 330 
that produces large quantity of TGF-beta, thereby stimulating fibrosis (74,75). The rapid and 331 
overwhelming synthesis of extracellular matrix results in the formation of scar tissue that 332 
ultimately prevents complete muscle healing (Figure 2: lower panel). Furthermore, persistent 333 
inflammatory cell activity causes the release of numerous pro-cachexia factors such as TNF-334 
alpha that stimulate muscle wasting (76). Inflammatory cells also release enzymes and 335 
oxidative factors that lead to cell membrane leakage and cause additional collateral damage 336 
to the muscle. In summary, the perturbation of muscle repair by repetitive local injuries 337 
contributes to an excessive and/or persistent inflammatory process and subsequently to the 338 
progression of the disease and muscle dysfunction. 339 
  340 
The impact of anti-inflammatory drugs on muscle healing in chronic inflammatory 341 
conditions.  342 
Medical management of patients with chronic inflammatory conditions is a 343 
challenging clinical problem faced by health professionals. Treatment plans usually include 344 
long-term NSAID or steroidal anti-inflammatory drugs (SAID) administration. Contrary to 345 
what is observed in acute muscle injuries, the use of anti-inflammatory drugs may have 346 
potential beneficial effects on some chronic muscle disorders. For instance, the 347 
administration of prednisone following asynchronous injuries, induced by delayed injections 348 
of notexin, was shown to blunt the chronic inflammatory condition, which diminished the 349 
production of TGF-beta and reduced muscle fibrosis (71). Thus, SAID administration 350 
restored the balance in the inflammatory process and improved muscle regeneration. Similar 351 
observations were also made in dystrophic muscles, which are subjected to an uncontrolled 352 
inflammatory process. SAID administration reduced muscle damage in the diaphragm of 353 
dystrophin-deficient mdx mice (mouse model of Duchenne muscular dystrophy) (77), and 354 
increased grip strength, motor coordination and maximum force of extensor digitorum longus 355 
(EDL) muscles (78). Similarly, SAID treatment to young boys suffering from DMD prolongs 356 
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mobility, improves cardiac and pulmonary function and delays the need for assistance with 357 
feeding (79). However, both in mice and humans, the positive effects of SAIDs are limited in 358 
time and are progressively lost after a few months to years (78,80). Part of this time-limited 359 
effect might be caused by the fact that while SAIDs are very efficient at downregulating 360 
inflammatory activity, their prolonged use can have harmful side effects. For instance, 361 
glucocorticoids activate cellular signalling pathways involved in protein degradation, which 362 
promotes muscle atrophy (81). Moreover, SAIDs reduce the proliferation and differentiation 363 
of myoblasts (82). Thus, while the dampening of the chronic inflammatory process is 364 
responsible for the short-term beneficial effect of SAIDs on muscle healing in DMD, the long-365 
term administration of these pharmacological agents potentially contributes to muscle 366 
wasting.  367 
The efficiency of anti-inflammatory drugs on muscle healing also depends on the origin of 368 
the inflammatory process, i.e. local or systemic. For example, COPD is usually associated 369 
with systemic inflammation, which correlates with muscle fiber type changes, muscle 370 
atrophy, and impaired muscle regeneration. Several randomised controlled trials studied the 371 
impact of anti-inflammatory therapies on the muscles of patient suffering from COPD; 372 
however all have failed to show significant improvement in muscle function (83). Similarly, it 373 
was shown that NSAID administration to aged patients with low-grade chronic inflammation 374 
is inefficient in decreasing systemic inflammation and does not affect muscle response to 375 
exercise (84). Furthermore, NSAID administration to patients suffering from osteoarthritis 376 
(which is correlated with a low-grade systemic inflammation (85)) did not affect exercise-377 
induced response (86). Therefore, NSAIDs are usually inefficient to treat conditions 378 
associated with a systemic inflammatory response. 379 
In summary, anti-inflammatory drugs could have beneficial and adverse effects on muscle 380 
regeneration depending on the chronic inflammatory state (local or systemic) and on the 381 
type of injury or disease. Thus, anti-inflammatory modalities could be part of a therapeutic 382 
 15 
strategy along with physical therapy in order to treat chronic disorders, but their use should 383 
be carefully selected based on scientific evidence. 384 
  385 
Therapeutic relevance 386 
In this manuscript we discussed fundamental and clinical articles to shed light on the current 387 
state of the literature regarding the effect of inflammation and anti-inflammatory modalities 388 
on muscle healing. As a result of our investigation, we propose a concept map for the use of 389 
anti-inflammatory modalities in a clinical setting (Figure 3). First, one should determine 390 
whether the condition involves an inflammatory response. Indeed, there is a common 391 
misconception among clinicians that chronic pain is always associated with chronic 392 
inflammation. However, many painful conditions such as tendinopathies are not clearly 393 
associated with inflammatory cell infiltration. Therefore, treating these patients with anti-394 
inflammatory modalities is primarily based on patient comfort assessment without 395 
considering the physiological impact of NSAID intake on tissue healing and the evidence-396 
based use of anti-inflammatory modalities. If the condition is associated with an inflammatory 397 
response, the clinician should determine whether it is acute or chronic. As discussed, a 398 
controlled and coordinated inflammatory process is beneficial for muscle healing. If the 399 
inflammation is considered chronic or excessive, the clinician should determine whether this 400 
inflammatory response is local or systemic. As demonstrated previously, anti-inflammatory 401 
modalities are usually effective to dampen local inflammation but not systemic inflammation. 402 
Thereafter, the appropriate anti-inflammatory treatment should be determined. The optimal 403 
modality should dampen the inflammatory process (which is not the case for many 404 
approaches whose effects are mostly analgesic) and its use should have been validated by 405 
clinical studies for that specific condition. Finally, clinicians must keep in mind that the 406 
prolonged use of systemic anti-inflammatory modalities such as SAIDs might have 407 
detrimental side effects on skeletal muscle by promoting muscle wasting. 408 
 409 
Perspectives 410 
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Overall, inflammation and muscle regeneration are closely interconnected through complex 411 
cellular, physical and chemical interactions. In acute conditions, these interactions are 412 
beneficial for muscle healing; however, they can also be detrimental in chronic or excessive 413 
inflammatory conditions. Therefore, the therapeutic plan of physiotherapists must take into 414 
account the delicate balance between the reduction of the excessive inflammatory state and 415 
muscle regeneration (Figure 3). As the elderly population grows, physiotherapists will 416 
increasingly be confronted to complex local and systemic inflammatory conditions. 417 
Therefore, there is a need for professional updates on evidence-based use of anti-418 
inflammatory modalities (5). This perspective paper was intended to build a bridge between 419 
fundamental research and clinical use of anti-inflammatory modalities. In a few years, we will 420 
be able to evaluate the effect of NSAID prescription on the clinical practice of UK 421 
physiotherapists. Therefore, additional studies will be needed to further characterize the 422 
effect of anti-inflammatory modalities on musculoskeletal healing to ensure that fundamental 423 
evidence translates into effective clinical practices in physiotherapy. 424 
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Figure legends  698 
 699 
Figure 1: The activity of satellite cells during muscle regeneration 700 
Following an injury (day 0), resting satellite cells (adult muscle stem cells) are activated and 701 
start proliferating (day 1). The proliferating cells (myoblasts) reach their peak approximately 702 
3 days after the injury, when they will stop proliferating and start to differentiate. 703 
Differentiated myoblasts will fuse into myotubes (immature myofibers) around day 4 to 7 704 
after the injury. Newly formed myofibers will grow into mature myofibers over the next few 705 
weeks. Satellite cells will return to their resting state, but will be poised for a future injury. 706 
The satellite cells are guided through these different phases by the activity of inflammatory 707 
cells (see Figure 2). 708 
 709 
Figure 2: Effect of acute and chronic inflammatory processes on muscle regeneration. 710 
In the context of acute inflammation (upper panel), neutrophils and pro-inflammatory 711 
macrophages (M1) massively accumulate in the injured muscle. The M1 macrophages 712 
release a variety of pro-inflammatory agents such as TNF-α (tumor necrosis factor-alpha) 713 
that will foster the activation and proliferation of satellite cells. Thereafter, during the phase 714 
of resolution of the inflammatory process, the M1 macrophages switch to an anti-715 
inflammatory phenotype (M2). M2 macrophages stimulate the differentiation of myoblasts in 716 
myotubes and promote the growth of muscle fibers. In chronic inflammation (lower panel), 717 
the persistence of neutrophils impairs macrophage conversion from M1 to M2 profile and 718 
these cells adopt a hybrid phenotype, which impairs muscle healing and triggers fibrosis by 719 
releasing an exaggerate amount of TGF-beta. 720 
 721 
Figure 3: Concept map for the use of anti-inflammatory modalities 722 
This decision-making tree shows the general guidelines for the evidence-based use of anti-723 
inflammatory modalities for the treatment of muscle disorders in a clinical setting. 724 
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 740 
Table 1: Brief description of the different cell types discussed in this manuscript 741 
 742 
Cell	types	 Description	
Satellite	cells	 Adult muscle stem cells responsible for muscle healing. Satellite 
cells are inactive in a resting muscle. 
Myoblasts	 Activated satellite cells that proliferate and differentiate during 
muscle regeneration. 
Myotubes	 Multinucleated cells formed by the fusion of myoblasts.  
Immature myofibers 
Myofibers	 Multinucleated cells that contains the contractile proteins responsible 
for muscle contraction. 
Mast	cells	 Inflammatory cells residing in different tissues. Once activated they 
play a key role in the initiation of the inflammatory process 
Neutrophils	 Inflammatory cells that circulate in blood and rapidly infiltrate a tissue 
after an injury where they play a key role in debris clearance. 
Monocytes	 Inflammatory cells that circulate in blood and infiltrate the injured 
tissue where they differentiate into macrophages. 
Macrophages	 Inflammatory cells which can switch from a pro-inflammatory 
phenotype (M1) to an anti-inflammatory phenotype (M2). 
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